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ment in chronic HCV infected patients with thrombocytopenia to enable INF-based 
treatment regimens from the Spanish Health System perspective. Methods: A 
two-phase individual-level model was developed to evaluate the cost-effectiveness 
of eltrombopag treatment in thrombocytopenic HCV-patients over a lifetime hori-
zon. Individual-level models are more flexible and provide more accurate estima-
tions than Markov approaches. One million patients were simulated using data from 
trials ENABLE 1 and 2 and local studies. In the first phase, a discrete event simulation 
was used to recreate patient events during INF-treatment. When eltrombopag was 
considered, patients underwent an initial pre-INF treatment with eltrombopag. 
Those that failed to reach INF-label platelet count did not receive INF-based regi-
mens. In the second phase, a microsimulation was used to emulate each patient 
from treatment discontinuation to death. Health states included fibrosis (F0, F1/2, 
F3, F4), liver decompensation, hepatocelullar carcinoma, liver transplant and death. 
Transition probabilities for each 1-month cycle, utilities and direct health care costs 
(€ 2014) were obtained from literature and national databases. A 3% annual discount 
was applied to costs and health outcomes. Sensitivity analysis with 0% and 5% 
discount rates were performed. Results: Eltrombopag was associated with an 
average increment of 0.58 quality-adjusted life years (QALY) and an additional cost 
of € 17,084.47/patient. The average incremental cost effectiveness ratio (ICER) was 
29,808.26 € /QALY. Considering a € 30,000 threshold, eltrombopag was cost-effective 
in 59.12% of cases. This proportion remained similar with 5% (56.7%) and 0% (63.25%) 
discount rates. ConClusions: With the premises considered in this study, eltrom-
bopag in HCV patients could be considered cost-effective from the Spanish Health 
System perspective.
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objeCtives: To assess the cost-effectiveness of romiplostim in the treatment of 
Adult Immune Thrombocytopenia (ITP) in Portugal, versus eltrombopag and current 
medical standard of care (SoC). Methods: A lifetime treatment-sequence cost-utility 
Markov model with an embedded decision tree was developed from the Portuguese 
Healthcare Payer perspective to compare romiplostim with eltrombopag and SoC in 
splenectomized patients, non-splenectomized patients and a combined population. 
Treatment sequences and health care utilization were validated by a Portuguese 
expert in ITP. Outcomes included incremental cost-utility ratio (ICUR). Costs (€ , 2014) 
included drug acquisition costs and costs associated with monitoring patients and 
managing complications. Results: In the combined population, romiplostim versus 
eltrombopag had incremental costs (IC) of 13.848€ and a quality-adjusted life-years 
(QALY) gain of 0,566, yielding an ICUR of 24.451€ . Compared with SoC, romiplostim 
had IC of 18.622€ and a QALY gain of 0,938, yielding an ICUR of 19.848€ . In splenecto-
mized patients, the most prevalent sub-population in Portugal (65% of adult chronic 
ITP patients), romiplostim had an ICUR of 6.304€ versus eltrombopag and an ICUR 
of 3.179€ versus SoC. One-way sensitivity analysis showed that the model was most 
sensitive to variations in the drug doses/ percentage of utilization and costs (romi-
plostim, eltrombopag and intravenous immunoglobulin) and to the utility of patients 
responding to ITP treatments. In the combined population the probabilistic sensitiv-
ity analysis showed that romiplostim is likely to be cost-effective in 66% and 84% of 
samples versus eltrombopag and versus SoC at a willingness-to-pay threshold of 
30.000€ /QALY, respectively. ConClusions: Use of romiplostim in the ITP treatment 
pathway, compared with eltrombopag or SoC, is likely to be cost-effective in Portugal.
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objeCtives: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune inflam-
matory disease, associated with significant health and socioeconomic burden. 
Current treatment of SLE involves glucocorticoids, antimalarials, non-steroid anti-
inflammatory drugs, and immunosuppressive agents. Belimumab, a human IgG 
monoclonal antibody specific for soluble human B lymphocyte stimulator protein, 
is a novel pharmaceutical treatment approved as an add-on therapy in adult SLE 
patients with highly active disease (autoantibody-positive and low complement 
levels) despite treatment. The study objective was to estimate the incremental 
cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) of adding 
belimumab to the Standard-of-Care (SoC) treatment of SLE patients with high dis-
ease activity in the Greek health care setting. Methods: The analysis is based on 
the local adaptation of a micro-simulation model. The model follows individual 
patients over a lifelong period. Data on short-term outcomes were sourced from two 
randomized controlled trials (BLISS 72/7614). Long-term outcomes were estimated 
via natural history models developed on the basis of data from the John Hopkins 
cohort of SLE patients. Direct costs consisted of short-term disease activity related 
costs, organ damage costs, SoC treatment and belimumab administration costs. 
Short-term costs and costs of treatment were calculated on the basis of resource 
utilisation elicited from a panel of experts and using list prices (2013 prices). Organ 
damage costs were identified through a literature review. Results were discounted at 
3.5% for both costs and effects. The study was performed from the perspective of the 
health care payer. Results: Treatment with belimumab+SoC resulted in 0.81 added 
life years and 0.377 QALYs (Quality-Adjusted Life Years). This resulted in 18,350€ / 
LYG (Life-Year-Gained) and 27,254€ /QALY. ConClusions: Cost-effectiveness and 
cost-utility ratios of belimumab compared to SoC treatment are below internation-
ally applied thresholds. Belimumab can be considered as an add-on therapy to SoC 
for the treatment of SLE patients with highly active disease in Greece.
strength of the analysis, deterministic and probabilistic sensitivity tests were per-
formed; all the quantities are expresed in Mexican pesos (MXP) at 2013. Results: 
Both groups lose weight and reduce their BMI. However, these changes were earlier 
and more pronounced in the (DEP+DaE) group. DeP+DaE presented a significant 
higher percentage of patients reducing 10% of their intial weight (37% vs 17%, 
p-value< .05). Incremental cost was $1,455.09 MXP and incremental effectiveness 
was 20% in reducing the initial weight. The incremental cost-effectiveness ratio of 
(DEP+DaE) relative to DaE was calculated to be $7,374.07 MXP per additional percent-
age of reduction suggesting that DEP+DaE is cost-effective compared with DaE as 
a treatment for obesity in Mexico. ConClusions: The combination of DEP+DaE 
provides a cost effective improvement to the treatment of patients with a risk profile 
for obesity in Mexico.
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objeCtives: To perform a complete economic evaluation type using oxycodone 
(Endocodil XR ®) versus morphine, buprenorphine (transdermal patches) and fen-
tanyl (transdermal patches) on moderate to severe pain secondary to cancer type 
in Mexico, from the point of view of public health. Methods: A cost-effectiveness 
analysis was made, a decision tree model was developed to simulate the costs and 
benefits of health outcomes of each opioid analgesic, the probabilities were obtained 
through a systematic review of the literature. The model has 13 cycles of 28 days 
under a time horizon of 364 days, the main measure of effectiveness was deter-
mined as days without severe adverse events and pain controlled, only measured 
direct medical costs and the ratio was obtained incremental cost-effectiveness, 
further a deterministic sensitivity analysis, probabilistic sensitivity analysis and 
budget impact was performed. Results: The results demonstrate that oxycodone 
(Endocodil XR ®) is a dominant option respect to Buprenorphine (PT), fentanyl (PT), 
the results showed 309 days without severe adverse events and controlled pain 
compared to 219 and 255 respectively Oxycodone had a cost of $ 57,702.34 under $ 
58,254.43 and 129,906.49 costing of their comparators respectively, compared to mor-
phine oxycodone is more effective but more expensive, it had an ICER of $ 202.05, 
sensitivity analysis and budget impact showed that oxycodone remains an option 
cost-saving. ConClusions: The results demonstrate that oxycodone (Endocodil XR 
®) is a cost-effective option for the treatment of patients with pain of moderate to 
severe secondary to cancer in Mexico, it is an option that effectively combines price 
and fails to meet the necessary standards for palliative care and pain management.
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objeCtives: To perform ñomparative pharmacoeconomic analysis of alternative 
schemes for prevention of invasive mycosis with fluconazole, itraconazole and 
posaconazole in patients with neutropenia, after chemotherapy for acute myelog-
enous leukemia or myelodysplastic syndrome. Methods: Were reviewed research 
on the clinical effectiveness and safety of use of Posaconazole. Assess of the qual-
ity of research and level of evidence obtained in these results was performed. The 
model is constructed on the basis of the results of a multicenter randomized trial 
Cornely O. A. et al., 2007. The model calculated the differences in direct medical 
costs for the use of drugs, as well as the cost of medical treatment cases inva-
sive mycosis the ineffectiveness of primary prevention. The duration of preventive 
treatment, the probability of various outcomes correspond to the data of speci-
fied clinical study. Results: Analysis of the evidence has shown that on patients 
with neutropenia antifungal prophylaxis with posaconazole is more effective than 
fluconazole/itraconazole, and significantly reduces the risk of developing invasive 
mycosis, and associated mortality. Total costs for the use of posaconazole was 13169 
USD, that by 24.6 % higher than the use of fluconazole (total costs 9932 USD) and 
24.3 % higher than itraconazole (total costs 9965 USD). Also use of posaconazole has 
increased the total number of LYG by 6%. The ICER was $ 21339 USD and 21117 USD 
compared to fluconazole and itraconazole, and lower than the estimated threshold 
of willingness to pay in the Russian Federation equal 38390 USD. One-way sensi-
tivity analysis showed that in case of changes in the cost of posaconazole from 
75% to 125 %, the ICER for a one LYG do not exceed the threshold of willingness 
to pay. ConClusions: Use of Posaconazole for prevention of invasive mycosis in 
patients with neutropenia is economically justified.
PSY62
CoSt-EffECtivEnESS analYSiS of EltRomboPag aS SuPPoRt tREatmEnt 
in ChRoniC hCv infECtEd PatiEntS With thRomboCYtoPEnia to EnablE 
intERfERon-baSEd REgimEnS
Parrondo J.1, Rincón Rodríguez D.2, Romero Gómez M.3, Sola Lamoglia R.4, Roldán C.1
1GSK Spain, Tres Cantos, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, 
Spain, 3Hospital Universitario de Valme. Universidad de Sevilla, Sevilla, Spain, 4Hospital del Mar 
IMIM - Universitat Autonoma de Barcelona, Barcelona, Spain
objeCtives: Thrombocytopenia limits the use of interferon (INF) based regimens 
in chronic hepatitis C virus (HCV) patients. Eltrombopag, a thrombopoietin-receptor 
agonist, effectively elevates platelet count allowing optimal INF-treatment. The 
objective of the present study was to assess the cost-effectiveness as support treat-
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objeCtives: Venous thromboembolism (VTE) is a frequent but preventable compli-
cation in hospitalized patients. The objective of this population-based simulation 
was to estimate, for Saudi Arabia and using a British (NICE) model, the cost-effi-
ciency of partial versus complete thromboprophylaxis of hospitalized adult patients 
at medium-to-very-high (M2VH) -VTE risk. Methods: Simulation including all 2012 
Saudi adult medical (n= 2,129,866) and surgical (n= 964,033) hospital admissions, 
expressed in Saudi riyals (SAR), using three scenarios based on published real-
world thromboprophylaxis studies: (1) international study and (2) Saudi subsample 
thereof (Cohen et al, Lancet 2008), and (3) Middle-Eastern study (Mokhtari et al, J 
Thromb Haemost 2011). Variables included rates for: high bleeding risk (mechanical 
versus pharmacoprophylaxis); major bleeding episode (MBE) secondary to pharma-
coprophylaxis; deep vein thrombosis (DVT; pulmonary embolism (PE); and 12-month 
DVT/PE readmission following such discharge diagnosis. Costs considered were: 
thromboprophylaxis; management of MBE, DVT, PE; and 12-month DVT/PE read-
mission. Results: Scenario (1): total costs for partial and complete prophylaxis 
were SAR631,462,830 and SAR508,957,517 for a complete-over-partial cost-avoidance 
by 24.1% of SAR122,505,313/year (SAR92.14 per patient and SAR167.83 per patient 
at VTE risk). Scenario (2): total costs for partial and complete prophylaxis were 
SAR712,441,824 and SAR600,483,584 for a complete-over-partial cost-avoidance 
by 18.6% of SAR111,958,239/year (SAR77.35 per patient and SAR127.58 per patient 
at VTE risk). Scenario (3): total costs for partial and complete prophylaxis were 
SAR749,939,936 and SAR647,300,590 for a complete-over-partial cost-avoidance by 
15.9% of SAR102,639,346/year (SAR62.77 per patient and SAR97.84 per patient at VTE 
risk). ConClusions: In this population-based cost-efficiency simulation for Saudi 
Arabia, thromboprophylaxis of all admitted M2VH-VTE risk versus partial methods 
is associated with significant cost savings per year. Considering the associated 
reductions in DVT, PE, and readmissions, even under increased pharmacoprophy-
laxis-related MBE risk and costs, complete thromboprophylaxis of (M2VH) -VTE risk 
patients achieves the Institute for Healthcare Improvement Triple Aim of better care, 
better patient outcomes, and reduced costs.
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objeCtives: Approximately 15-35% of patients with hemophilia A develop inhibi-
tory antibodies to factor VIII. There are currently two bypassing agents to treat 
inhibitor patients in the case of bleeding episodes (BE) and preemptively before 
and during major surgeries. Both APCC and rFVIIa demonstrated similar efficacy 
and safety results. Our aim was to compare the costs of bypass strategy based on 
APCC or rFVIIa while we included only drug acquisition costs, and from them we 
derived costs of bleeding episodes and surgery costs in Hungary, Slovakia, Slovenia 
and Serbia. Methods: For the purpose of cost comparison, we developed a model 
using cost-minimization approach which included only the costs of APCC or rFVIIa. 
We assessed the cost differences for two basic scenarios - patients with bleeding 
episodes and patients undergoing major surgeries. The doses used in model were: 
i) BE APCC 62.5 U/kg, ii) surgery APCC 85 U/kg, iii) BE and surgery rFVIIa 90 μ g/kg. 
The doses are based on the SmPCs (middle of given dose intervals) and published 
literature (in the case of APCC used in surgery which is administered in higher doses 
in clinical practice compared to declaration in SmPC). Results: In the scenario 
of bleeding episodes, the use of APCC instead of rFVIIa brings the potential sav-
ings € 4,596-8,704; € 5,135-9,347; € 5,738-10,807; € 4,369-8,527 respectively in Hungary, 
Slovakia, Slovenia and Serbia (depending on the dosing scheme). While using APCC 
during major surgeries, the savings are equal to € 157,159 (if compared to rFVIIa 
therapy) and € 15,616 (if compared to the combination therapy of APCC and rFVIIa) 
in Hungary; € 180,653 and € 16,558 in Slovakia; € 196,965 and € 19,362 in Slovenia; 
and € 145,979 and € 15,422 in Serbia. ConClusions: The potential savings by using 
APCC instead of rFVIIa are significant for health care systems, APCC thus indirectly 
enables more treated patients for the same health care costs consumption.
PSY70
CoSt-minimization analYSiS of mEthadona oPioid analgESiC foR 
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objeCtives: Perform a full economic evaluation of cost minimization of the use 
of Methadone versus oxycodone (extended release), buprenorphine (transdermal 
patches), fentanyl (transdermal patches) and hydromorphone in opioid rotation 
for patients with acute severe pain secondary to cancer and chronic type as rota-
tion option in Mexico, from the point of view of public health. Methods: A sys-
tematic literature review was conducted to identify articles and extract data of 
safety and efficacy and compare the available alternatives: methadone, oxycodone, 
buprenorphine (PT), fentanyl (PT) and hydromorphone. Based on the results of this 
systematic review was identified that 5 alternatives presented safety and efficacy 
profiles without significant differences. Economic evaluation corresponded to a 
cost minimization, the analysis was performed with three subgroups with rotation 
of opioids, each subgroup received a certain amount of morphine (80mg, 160mg, 
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objeCtives: To assess the incremental cost-utility ratio (ICUR) of bosutinib for CML 
as a third-line (3L) treatment for chronic phase (CP) Philadelphia chromosome-
positive (Ph+) patients in Portugal compared to hydroxycarbamide, in the societal 
perspective. Methods: A survival analysis model was adapted to the Portuguese 
setting. Bosutinib overall survival was based on Study 200, an open-label phase I/
II single-arm study of Ph+ CML patients. Overall survival with hydroxycarbamide 
and time spent in the accelerated and blastic phases, that are assumed to be inde-
pendent of treatment, were estimated by an expert panel of five Portuguese hae-
matologists. Resource consumption was elicited by this expert panel, being unit 
costs based on Portuguese official sources. Utility values were adapted from the IRIS 
study. A 5% discount rate was applied to both costs and consequences on a 50-year 
time horizon. Results: The use of bosutinib allows an increase of 4.1 life years 
(LY) and 3.5 quality adjusted life years (QALY), being associated to an additional 
cost of 88,319€ . Consequently, cost per LY is 21,465€ and cost per QALY is 25,252€ . 
Sensitivity analysis shows that results are mainly driven by survival time gained 
with bosutinib. ConClusions: Bosutinib for CML 3L treatment for CP patients 
in Portugal represents a substantial added benefit relative to hydroxycarbamide 
although with added costs per LY and per QALY. These ratios are generally accepted 
in Portugal, both below 30,000€ willingness to pay threshold.
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objeCtives: To assess the cost-effectiveness of romiplostim in the treatment 
of adult patients with ITP in the Czech Republic, in comparison with the medi-
cal standard of care (SoC) and eltrombopag. Methods: A lifetime treatment 
sequence cost-utility Markov model was developed from the health care payer 
perspective. The model was based on the treatment sequences that reflect cur-
rent practice for ITP management and was driven by platelet response (platelet 
count ≥ 50x109/L), which determined effectiveness and progression along the treat-
ment pathway, need for rescue therapy and risk of bleeding. Costs were derived 
from reimbursement lists available in January 2013. Four scenarios were con-
ducted where romiplostim was compared with SoC with rituximab, SoC without 
rituximab, SoC without both rituximab and mycophenolate mofetil (MMF), and 
eltrombopag. Patients were evaluated by splenectomy status and for the combined 
population (CP). Results: Compared to SoC with rituximab, romiplostim was 
dominant in splenectomised patients and CP, with cost savings of 2,203,982CZK 
and 1,078,899CZK and gains of 1.58 and 1.81 quality-adjusted life-years (QALYs), 
respectively, and was cost-effective in non-splenectomised patients with an ICER 
of 44,107 CZK/QALY. Compared to eltrombopag, romiplostim was dominant in 
splenectomised patients and CP, with cost savings of 1,626,409CZK and 741,613CZK 
and gains of 1.12 and 1.21 QALYs, respectively, and was cost-effective in non-
splenectomised patients with an ICER of 74,266 CZK/QALY. Similar results were 
shown in the other two scenarios: romiplostim was dominant in splenectomised 
patients and CP compared to SoC without rituximab and SoC without both rituxi-
mab and MMF, and was cost-effective in non-splenectomised patients with ICERs 
of 51,011CZK/QALY (SoC without rituximab) and 41,192CZK/QALY (SoC without 
rituximab and MMF). ConClusions: Romiplostim was less costly with higher 
QALY gain compared to SoC and eltrombopag in splenectomised patients and CP. 
Romiplostim was cost-effective with ICERs between 41,000 and 74,000CZK/QALY 
in all non-splenectomised populations in all four scenarios.
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objeCtives: To evaluate the cost-effectiveness of celecoxib compared with loxo-
profen for the treatment of patients with chronic pain caused by osteoarthritis, 
rheumatoid arthritis and low back pain in Japan. Methods: Using the Markov 
model, long-term simulations were conducted with a 3-month Markov cycle for 
each regimen of celecoxib vs. loxoprofen in the perspective of Japanese health 
care payers. The direct medical costs and quality-adjusted life years (QALYs) were 
estimated as outcome measures throughout the lifetime of patients. The base 
case population was aged 57 years which was the weighted mean age from the 
cited literature. All the costs were expressed as of March 2014, and annual dis-
count rates of 2% were applied for both costs and health benefits. Results: The 
incremental effectiveness of celecoxib compared with loxoprofen was 0.024 QALY 
while the incremental cost was JPY 73,785 (USD 716, USD 1 = JPY 103), indicating 
the incremental cost-effectiveness ratio (ICER) was JPY 3,131,480 (USD 30,403) per 
QALY gained. Sensitivity analyses identified two factors substantially sensitive to 
ICER: 1) decrease in efficacy of celecoxib in the recurrence of symptomatic ulcer, 
and 2) increase in utility of the primary disease that causes chronic pain while the 
administration of the drug halts. The literature review, however, supported that 
both of those sensitive cases are not so much likely to happen. ConClusions: 
Celecoxib was considered cost-effective compared with loxoprofen in patients 
with chronic pain in Japan.
